{"Trastuzumab": [0], "deruxtecan": [1, 49, 59, 85, 117, 185, 315], "(DS-8201)": [2], "is": [3], "an": [4, 9], "antibody-drug": [5], "conjugate": [6], "composed": [7], "of": [8, 36, 57, 107, 115, 133, 161, 175, 183, 190, 217, 242, 262, 274, 298, 344], "anti-HER2": [10], "(human": [11], "epidermal": [12], "growth": [13], "factor": [14], "receptor": [15], "2)": [16], "antibody,": [17], "a": [18, 23, 29, 34, 45, 120, 173, 197, 268, 321, 342], "cleavable": [19], "tetrapeptide-based": [20], "linker,": [21], "and": [22, 131, 163, 166, 238, 280, 311, 334, 346, 352, 359], "cytotoxic": [24], "topoisomerase": [25], "I": [26], "inhibitor.": [27], "In": [28, 103, 193, 330], "phase": [30, 79], "1": [31, 302], "dose-finding": [32], "study,": [33, 81, 109, 256], "majority": [35], "the": [37, 104, 108, 124, 129, 134, 142, 155, 180, 194, 239, 255, 257, 275, 287, 299], "patients": [38, 61, 169, 205, 300, 345], "with": [39, 62, 69, 88, 100, 292, 325], "advanced": [40], "HER2-positive": [41, 63, 91, 326], "breast": [42, 65, 93, 328], "cancer": [43, 66, 94], "had": [44, 96, 171], "response": [46, 51, 162, 198, 228], "to": [47, 118, 146, 199, 212, 224, 236, 251, 332, 349], "trastuzumab": [48, 58, 70, 84, 101, 116, 184], "(median": [50], "duration,": [52], "20.7": [53], "months).": [54], "The": [55, 137, 214, 226], "efficacy": [56, 130], "in": [60, 86, 123, 203, 296, 320, 341], "metastatic": [64, 92, 327], "previously": [67], "treated": [68], "emtansine": [71], "requires": [72, 347], "confirmation.In": [73], "this": [74], "two-part,": [75], "open-label,": [76], "single-group,": [77], "multicenter,": [78], "2": [80], "we": [82, 110, 127], "evaluated": [83, 111, 128], "adults": [87], "pathologically": [89], "documented": [90], "who": [95, 170], "received": [97, 179], "previous": [98, 177], "treatment": [99], "emtansine.": [102], "first": [105], "part": [106], "three": [112], "different": [113], "doses": [114], "establish": [119], "recommended": [121, 135, 181], "dose;": [122], "second": [125], "part,": [126], "safety": [132], "dose.": [136], "primary": [138], "end": [139, 152], "point": [140], "was": [141, 201, 219, 230, 245, 290, 339], "objective": [143], "response,": [144], "according": [145], "independent": [147, 285], "central": [148], "review.": [149], "Key": [150], "secondary": [151], "points": [153], "were": [154, 267], "disease-control": [156], "rate,": [157, 159], "clinical-benefit": [158], "duration": [160, 216, 229, 241], "progression-free": [164, 243], "survival,": [165], "safety.Overall,": [167], "184": [168], "undergone": [172], "median": [174, 215, 227, 240], "six": [176], "treatments": [178], "dose": [182], "(5.4": [186], "mg": [187], "per": [188], "kilogram": [189], "body": [191], "weight).": [192], "intention-to-treat": [195], "analysis,": [196], "therapy": [200], "reported": [202], "112": [204], "(60.9%;": [206], "95%": [207], "confidence": [208], "interval": [209], "[CI],": [210], "53.4": [211], "68.0).": [213], "follow-up": [218], "11.1": [220], "months": [221, 232, 247], "(range,": [222], "0.7": [223], "19.9).": [225], "14.8": [231], "(95%": [233, 248], "CI,": [234, 249], "13.8": [235], "16.9),": [237], "survival": [244], "16.4": [246], "12.7": [250], "not": [252], "reached).": [253], "During": [254], "most": [258], "common": [259], "adverse": [260], "events": [261], "grade": [263, 306, 312], "3": [264, 307], "or": [265, 303, 308], "higher": [266], "decreased": [269], "neutrophil": [270], "count": [271], "(in": [272, 278, 282], "20.7%": [273], "patients),": [276], "anemia": [277], "8.7%),": [279], "nausea": [281, 333], "7.6%).": [283], "On": [284], "adjudication,": [286], "trial": [288], "drug": [289], "associated": [291], "interstitial": [293, 336], "lung": [294, 337], "disease": [295, 338], "13.6%": [297], "(grade": [301], "2,": [304], "10.9%;": [305], "4,": [309], "0.5%;": [310], "5,": [313], "2.2%).Trastuzumab": [314], "showed": [316], "durable": [317], "antitumor": [318], "activity": [319], "pretreated": [322], "patient": [323], "population": [324], "cancer.": [329], "addition": [331], "myelosuppression,": [335], "observed": [340], "subgroup": [343], "attention": [348], "pulmonary": [350], "symptoms": [351], "careful": [353], "monitoring.": [354], "(Funded": [355], "by": [356], "Daiichi": [357], "Sankyo": [358], "AstraZeneca;": [360], "DESTINY-Breast01": [361], "ClinicalTrials.gov": [362], "number,": [363], "NCT03248492.).": [364]}